Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060188 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT02060188 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 385 participants.
The verdict
NCT02060188, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Daratumumab
- DRUG Cobimetinib
- DRUG BMS-986016
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2014-03-12 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02060188
The ClinicalTrials.gov registry entry for NCT02060188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02060188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02060188 about?
NCT02060188 is a clinical study titled "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread". The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.
What is the current status of trial NCT02060188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2014-03-12. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT02060188?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Daratumumab (DRUG), Cobimetinib (DRUG), BMS-986016 (DRUG).
Who is sponsoring clinical trial NCT02060188?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.